



October 15, 2002

Hans-Juergen Roethig, M.D., Ph.D.
Director, Clinical Evaluation
Philip Morris, Inc.
P. O. Box 26583
Richmond, VA 23261-6583

Dear Dr. Roethig:

I want to take this opportunity to update you with respect to Radiant Research and our capabilities in the area of Phase I/Clinical Pharmacology. Our focus in this area has been on confinement studies at four of our research centers with access to special populations including Japanese bridging, renal impairment, diabetes, arthritis, post-menopausal females, osteoporosis, and elderly.

This year at the AAPS Annual Meeting in Toronto, we will be hosting a wine and cheese reception and would like to invite you to join us. Held at the Fairmont Royal York Hotel from 5 – 8 p.m. on Monday, November 11, 2002 the reception will offer you an opportunity to discuss Japanese bridging studies and other clinical pharmacology studies with Dr. Jon Ruckle, Associate Medical Director for Radiant Research | Honolulu.

Our site in Honolulu has conducted over 15 Japanese bridging studies. They have a database of over 13,000 Japanese males and females of various ages participating in these clinical trials. All together the site has completed over 22 Clinical Pharmacology studies. Their database consists of over 45,000 subjects with almost 50% of them being post-menopausal females.

In Daytona Beach, FL, our site has participated in several first-in-man studies in patients with rheumatoid arthritis. They have also participated in studies involving diabetics and healthy volunteers. To date, they have completed over 20 Clinical Pharmacology studies. Their database consists of over 20,000 subjects.

Using an arthritis population, our Gainesville, FL site has conducted several first-in-man studies. Because Gainesville is home to the University of Florida they also have access to a large number of young healthy volunteers. To date they have completed over 30 Clinical Pharmacology studies. Their database consists of over 20,000 subjects.

Since their program began in 1990, our site in Austin, Texas has conducted over 65 clinical pharmacology studies in special patient populations. Of these, nearly half have been renal impairment studies involving subjects with varying stages of renal disease. In addition, they have conducted studies in subjects with hepatic impairment, hypertension, diabetes, post-menopausal females, osteoarthritis, rheumatoid arthritis, chronic bronchitis, emphysema, and migraine headaches. Their research database contains over 12,000 subjects. In addition they have access to a 115-physician multi-specialty clinic database of 125,000 active patients.

I would be happy to provide you with more specific information on each of our Phase I/Clinical Pharmacology sites. To request more information or inquire about our reception at the AAPS Annual Meeting in Toronto, please feel free to contact me at 513-247-5515 or robdanziger@radiantresearch.com.

Regards,

Rob Danziger
Senior Account Executive
Phone: 513-247-5515